Ekso Bionics Holdings Inc

Ekso Bionics Holdings Inc (NASDAQ: EKSO) specializes in the design, development, and commercialization of exoskeleton technologies. These products are intended to assist individuals with physical disabilities or mobility impairments, supporting both rehabilitation and everyday movement. The company operates through a single business segment, targeting two key markets: Enterprise Health and Personal Health.

Positive Growth Aspects

• Strategic Partnerships and Technological Advancement: Ekso Bionics demonstrated noteworthy progress in expanding its technological capabilities and market outreach. Notably, the company was accepted into the NVIDIA Connect program, a move that supports its strategic initiative to develop a proprietary AI foundation model for human motion. This collaboration has already yielded tangible results, such as the launch of the "Ekso Voice Agent" — an intelligent voice-controlled feature for the EksoNR device. This integration of AI into the company’s legacy products signals a forward-thinking approach and positions Ekso Bionics at the intersection of robotics, healthcare, and artificial intelligence. Additionally, the company named Bionic Prosthetics & Orthotics Group as its first distributor of the Ekso Indego Personal device, marking a significant expansion into the orthotics and prosthetics channel.
• Product Growth and Educational Outreach: The company reported strong momentum in its Personal Health segment, which grew over 50% year-over-year in the first half of 2025. This growth underscores rising demand and successful market penetration for the Ekso Indego Personal device. To further enhance the user experience and support healthcare professionals, Ekso launched "eksoUniversity," a platform providing continuing education courses tailored for physical therapists treating neurological conditions. These initiatives reflect Ekso’s commitment to broadening its ecosystem and reinforcing its value proposition through training, education, and community-building around its products.

Growth Challenges

• Revenue Decline and Margin Compression: Despite its innovation-driven initiatives, Ekso Bionics faced considerable financial headwinds during the second quarter of 2025. Revenue declined sharply to USD 2.1 million, down from USD 5.0 million in the same period in 2024 — a drop primarily attributed to delays in completing multi-device Enterprise Health sales. This weakness also significantly impacted gross profit, which fell to USD 0.8 million compared to USD 2.6 million in Q2 2024. The corresponding gross margin declined from 53% to 40%, affected by fixed costs on lower volumes, increased distribution-related low-margin sales, and rising shipping costs. These developments indicate operational inefficiencies and underscore the importance of achieving a steadier sales cadence in the Enterprise Health segment.
• Persistent Losses and Rising Administrative Costs: The company reported a net loss of USD 2.7 million for Q2 2025, widening from a USD 2.4 million loss a year earlier. Although sales and marketing as well as R&D expenses were modestly reduced — largely due to lower payroll and headcount — general and administrative expenses rose to USD 2.3 million, driven by fewer allocable costs to manufacturing. This uptick in non-revenue-generating expenses adds pressure on the company’s path to profitability. Furthermore, as of June 30, 2025, Ekso Bionics held a modest cash balance of USD 5.2 million, suggesting potential liquidity concerns if revenue recovery does not accelerate in the coming quarters.

Technical Observation (on the daily chart):

EKSO shows a long-term bearish trend, with the stock trading below both its 50-day and 200-day moving averages. Despite a recent short-term rebound, momentum has faded, as indicated by the RSI dropping to around 44 from recent highs. Price remains capped by resistance near the 50-day MA, and overall sentiment appears neutral to bearish.

Ekso Bionics delivered a mixed performance in Q2 2025, reflecting both strategic progress and financial headwinds. The company made notable strides by expanding its AI capabilities through the NVIDIA Connect program, launching the Ekso Voice Agent, and achieving over 50% year-over-year growth in its Personal Health segment. It also broadened market reach by naming its first orthotics and prosthetics distributor and launching an educational platform for therapists. However, the quarter was weighed down by a sharp 58% drop in revenue due to delayed Enterprise Health sales, reduced gross margins, and a widening net loss. Rising administrative costs and a limited cash position further highlight the need for improved execution and financial discipline in the second half of the year.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to Ekso Bionics Holdings Inc (NASDAQ: EKSO) at the current market price of USD 3.51 as of July 31,2025 at 9:40 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is July 31,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.